<DOC>
	<DOCNO>NCT01469000</DOCNO>
	<brief_summary>The purpose study compare combination pemetrexed gefitinib versus gefitinib alone , term progression-free survival . This study participants stage IV non squamous NSCLC activate epidermal growth factor mutation previous chemotherapy stage IV disease .</brief_summary>
	<brief_title>A Study Pemetrexed Gefitinib Versus Gefitinib Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically cytologically confirm advanced ( Stage IV ) recurrent nonsquamous NSCLC Eligible participant reproductive potential must agree use adequate contraceptive method study period least 6 month last dose study therapy Negative pregnancy test woman childbearing potential Males female , age 18 year Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 The participant 's primary NSCLC tumor activate Epidermal Growth Factor Receptor ( EGFR ) mutation , determine validate method The participant consent provide tissue sample prestudy EGFR mutation test tumor tissue sample available detection EGFR expression marker centralize test Lilly The participant measurable disease time study entry , document compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) , define Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 The participant prior systemic chemotherapy , immunotherapy , biological therapy ( example , target therapy , erlotinib gefitinib ) Stage IV recurrent nonsquamous NSCLC The participant adequate organ function , define : White blood cell count ≥3 x 10^9/liter ( L ) ; absolute neutrophil count ( segmented band ) ≥1.5 x 10^9/L ; platelet count ≥100 x 10^9/L ; hemoglobin ≥9.0 gram per deciliter ( g/dL ) Total bilirubin ≤1.5 time upper limit normal ( ULN ) range ; alkaline phosphatase ( AP ) , aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤2.5 time ULN ( ≤5 time ULN liver tumor involvement ) Calculated creatinine clearance ≥45 milliliter per minute ( mL/min ) The participant able take folic acid , vitamin B12 , dexamethasone , accord protocol 's requirement Life expectancy least 3 month Provision inform consent Prior radiation therapy allow &lt; 25 % bone marrow ; however , prior radiation whole pelvis allow . Prior radiation therapy must complete least 2 week prior first studydrug administration . Participants must recover acute toxic effect prior first studydrug administration . The participant receive prior chemotherapy advance and/or metastatic disease , adjuvant/neoadjuvant treatment pemetrexed EGFRtyrosine Kinase inhibitor ( TKI ) The participant ` tumor contains predominantly small cell lung cancer squamous NSCLC The participant receive concurrent treatment anticancer therapy , include chemotherapy , immunotherapy , hormonal therapy , chemoembolization , biological target therapy , radiotherapy ( palliative irradiation bone lesion allow ) The participant untreated central nervous system ( CNS ) metastases Participants treat brain metastasis eligible clinically stable regard neurologic function , steroid cranial irradiation ( whole brain radiation therapy , focal radiation therapy , stereotactic radiosurgery ) end least 2 week enrollment , surgical resection perform least 28 day enrollment . No evidence Grade ≥1 CNS hemorrhage base pretreatment MRI Intravenous ( IV ) contrast CT scan ( perform within 21 day randomization ) . The participant undergone radiotherapy within 28 day enrollment ( localized radiotherapy pain relief allow , provide 25 % less total bone marrow irradiate ) The participant clinically relevant congestive heart failure ( New York Heart Association [ NYHA ] IIIV ) symptomatic poorly control cardiac arrhythmia The participant serious illness medical condition would compromise safety impair ability comply protocol 's requirement , include , limited , following : Known human immunodeficiency virus ( HIV ) infection acquire immunodeficiency syndrome ( AIDS ) relate illness Active uncontrolled clinically serious infection Previous concurrent malignancy except basal squamous cell skin cancer and/or situ carcinoma cervix , solid tumor treat curatively without evidence recurrence least 5 year prior study Uncontrolled metabolic disorder nonmalignant organ systemic disease secondary effect cancer induce high medical risk and/or make assessment survival uncertain Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment Investigator would make participant ineligible entry study The participant significant third space fluid retention , amenable require repeated drainage Known allergy hypersensitivity reaction treatment component Are unable interrupt aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) , aspirin dose ≤1.3 gram per day , least 2 day ( 5 day longacting agent [ example , piroxicam ] ) , , least 2 day administration pemetrexed Concomitant use cytochrome P450 ( CYP ) 3A4 inducer CYP3A4 inhibitor Participants therapy warfarin coumarin derivative unable switch low molecular weight heparin , unless regular monitoring change prothrombin time ( PT ) ( PT/international normalize ratio [ INR ] ) applicable Any known significant ophthalmologic abnormality surface eye . The use contact lenses recommend study Are currently enrol , discontinue within last 30 day , clinical trial involve investigational product nonapproved use drug device , concurrently enrol type medical research judge scientifically medically compatible study Participants participate survey observational study eligible participate study The participant previously receive treatment gefitinib , erlotinib pemetrexed Any evidence clinically active interstitial lung disease . Asymptomatic participant chronic , stable , radiographic change eligible . Have preexist idiopathic pulmonary fibrosis evidence compute tomography ( CT ) scan/xray baseline ; disease acute lung injury , idiopathic pulmonary fibrosis , pulmonary pneumonia , pneumoconiosis evident xray ; disease radiation pneumonia druginduced pneumonia , require treatment corticosteroid . The participant pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>